Trials / Unknown
UnknownNCT04433169
All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
A Prospective, Open-label, Randomized Controlled Clinical Study to Evaluate the Efficacy and Safety of All-trans Retinoic Acid (ATRA) in the Treatment of Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, randomized controlled clinical intervention study to evaluate the efficacy and safety of all-trans retinoic acid (ATRA) in treating patients with recurrent metastatic adenoid cystic carcinoma of the head and neck.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | All-trans Retinoic Acid | ATRA 20 mg, three times a day, for 28 consecutive days, 28 days per cycle (q4w), 6 planned cycles |
| DRUG | VEGFR inhibitor | VEGFR inhibitor |
| DRUG | Chemotherapy | chemotherapy |
Timeline
- Start date
- 2020-06-03
- Primary completion
- 2022-12-01
- Completion
- 2023-06-01
- First posted
- 2020-06-16
- Last updated
- 2021-02-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04433169. Inclusion in this directory is not an endorsement.